| Switching NSAIDs in practice: insights from the Previcox (firocoxib) Experience Trial. | |
| | |
MedLine Citation:
|
PMID: 18183545 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Veterinarians currently have a choice of six registered NSAIDs for use in the management of canine osteoarthritis. There is a need for data to clarify whether there is an increased risk of side effects occurring in the event of a switch between different members of the NSAID class. In this retrospective analysis of extensive data collected in the 1,000 dog Previcox (firocoxib, Merial) Experience Trial, the incidence of side effects in dogs reported as treated with an NSAID 7 days or less before enrollment was compared with that in dogs reported as not having received an NSAID in the equivalent period. Statistical analysis of the data indicates that observation of an interval of up to 1 week between beginning treatment with firocoxib and cessation of treatment with a different NSAID was not associated with any increased risk of adverse events. |
| | |
Authors:
|
William G Ryan; Katherine Moldave; Doug Carithers |
Related Documents
:
|
20491235 - Side effects of stabilization occlusal splints: a report of three cases and literature ... 8573955 - Vigabatrin-associated reversible acute psychosis in a child. 20186675 - Cannabis-associated arteritis. 16150215 - Therapy-resistant psoriasis treated with alefacept and subsequent narrow band ultraviol... 6709145 - Epidural hematoma complicating paget's disease of the skull: a case report. 9987445 - Does use of the autopap assisted primary screener improve cytologic diagnosis? |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Veterinary therapeutics : research in applied veterinary medicine Volume: 8 ISSN: 1528-3593 ISO Abbreviation: Vet. Ther. Publication Date: 2007 |
Date Detail:
|
Created Date: 2008-01-09 Completed Date: 2008-02-28 Revised Date: 2012-10-26 |
Medline Journal Info:
|
Nlm Unique ID: 100936368 Medline TA: Vet Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 263-71 Citation Subset: IM |
Affiliation:
|
Ryan Mitchell Associates LLC, Westfield, NJ 07090, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
4-Butyrolactone
/
administration & dosage,
adverse effects,
analogs & derivatives,
therapeutic use Animals Anti-Inflammatory Agents, Non-Steroidal / administration & dosage, adverse effects, therapeutic use* Clinical Trials as Topic / veterinary* Databases, Factual Dogs Drug Administration Schedule Osteoarthritis / drug therapy*, pathology Patient Selection Research Design Retrospective Studies Sulfones / administration & dosage, adverse effects, therapeutic use Veterinary Drugs / administration & dosage, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Sulfones; 0/Veterinary Drugs; 189954-96-9/firocoxib; 96-48-0/4-Butyrolactone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Efficacy of selamectin and fipronil-(S)-methoprene spot-on formulations applied to cats against adul...
Next Document: Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronic o...